Articles that cite
this article:
Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells
S. Mumprecht, C. Claus, C. Schurch, V. Pavelic, M. S. Matter, A. F. Ochsenbein
113(19):4681. [CrossRef]
Generation of dendritic cells from peripheral blood of patients at different stages of chronic myeloid leukemia
C Zheng, P Pisa, O Stromberg, E Blennow, M Hansson
MO 17(4):270. [CrossRef]
Targeted therapies for the myeloid leukaemias
Peter Maslak, David Scheinberg
Expert Opin Invest Drugs 9(6):1197. [CrossRef]
BCR-ABL as a target for novel therapeutic interventions
T Kindler, RG Meyer, T Fischer
eott 6(1):85. [CrossRef]
Overcoming drug resistance in chronic myeloid leukemia
Jorge Cortes
Curr Opin Hematol 13(2):79. [CrossRef]
Joseph Jurcic, Kathleen Cathcart, Javier Pinilla-ibarz, David Scheinberg
Curr Opin Hematol 7(4):247. [CrossRef]
U. Osarogiagbon, Philip Mcglave
Curr Opin Hematol 6(4):241. [CrossRef]
Human acute myeloblastic leukemia cells differentiatein vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias
Aude Charbonnier, Béatrice Gaugler, Danielle Sainty, Marina Lafage-pochitaloff, Daniel Olive
Eur J Immunol 29(8):2567. [CrossRef]
Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia
Catherine J. Wu, Xiao-Feng Yang, Stephen Mclaughlin, Donna Neuberg, Christine Canning, Brady Stein, Edwin P. Alyea, Robert J. Soiffer, Glenn Dranoff, Jerome Ritz
J Clin Invest 106(5):705. [CrossRef]
Experimental non-ATP-competitive therapies for chronic myelogenous leukemia
A Quintás-cardama
22(5):932. [CrossRef]
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors
Johannes L Zakrzewski, David Suh, John C Markley, Odette M Smith, Christopher King, Gabrielle L Goldberg, Robert Jenq, Amanda M Holland, Jeremy Grubin, Javier Cabrera-perez
Nat Biotech 26(4):453. [CrossRef]
Cytotoxic T Cells
Mads Hald Andersen, David Schrama, Per Thor straten, Jürgen C Becker
J Invest Dermatol 126(1):32. [CrossRef]
Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia
Jochen Greiner, Michael Schmitt
Eur J Haematol 80(6):461. [CrossRef]
b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia
Louise C. Norbury, Richard E. Clark, Stephen E. Christmas
Br J Haematol 109(3):616. [CrossRef]
Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia
Jörg Westermann, Joachim Kopp, Antje Van lessen, Ann-Christine Hecker, Gökben Baskaynak, Philipp Le coutre, Konstanze Döhner, Hartmut Döhner, Bernd Dörken, Antonio Pezzutto
Br J Haematol 137(4):297. [CrossRef]
Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter-institute NIH study
Ramzi Dagher, Lauren M. Long, Elizabeth J. Read, Susan F. Leitman, Charles S. Carter, Maria Tsokos, Theresa J. Goletz, Nilo Avila, Jay A. Berzofsky, Lee J. Helman
Med Pediatr Oncol 38(3):158. [CrossRef]
Adoptive T-cell transfer in cancer immunotherapy
SIOK-KEEN Tey, CATHERINE M Bollard, HELEN E Heslop
Immunol Cell Biol 84(3):281. [CrossRef]
A listing of human tumor antigens recognized by T cells: March 2004 update
Luisa Novellino, Chiara Castelli, Giorgio Parmiani
Cancer Immunol Immunother 54(3):187. [CrossRef]
T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia
Jorg Westermann, Claudia Schlimper, Gunther Richter, Johannes Mohm, Bernd Dorken, Antonio Pezzutto
Br J Haematol 125(2):213. [CrossRef]
Induction of MTG8-specific cytotoxic T-cell lines: MTG8 is probably a tumour antigen that is recognized by cytotoxic T cells in AML1-MTG8-fused gene-positive acute myelogenous leukaemia
Motoi Maeda, Teruhisa Otsuka, Nobuhiro Kimura, Tomoko Kozu, Tomofusa Fukuyama, Naoyuki Uchida, Yasuhiro Sugio, Yoshikiyo Itoh, Tadafumi Iino, Shoichi Inaba
Br J Haematol 111(2):570. [CrossRef]
Recognition of chronic myelogenous leukaemia cells by autologous T lymphocytes primed in vitro against the patient's dendritic cells
Ludmila Muller, Carmelinda Provenzani, Christoph Faul, Graham Pawelec
Br J Haematol 112(3):740. [CrossRef]
Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis
Rolf E. Brouwer, Juliette Hoefnagel, Boudewijn Borger Van der burg, Inge Jedema, Koos H. Zwinderman, Ingrid C. W. Starrenburg, Hanneke C. Kluin-nelemans, Renee M. Y. Barge, Roel Willemze, J. H. Frederik Falkenburg
Br J Haematol 115(2):298. [CrossRef]
Adoptive immunotherapy with donor lymphocyte infusionsafter allogeneic HPC transplantation
F. Baron, Y. Beguin
Transfusion (Malden) 40(4):468. [CrossRef]
Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia
Maiko Matsushita, Hideyuki Ikeda, Masahiro Kizaki, Shinichiro Okamoto, Masahiro Ogasawara, Yasuo Ikeda, Yutaka Kawakami
Br J Haematol 112(4):916. [CrossRef]
Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia
Klaus Eisendle, Alois Lang, Brigitte Eibl, David Nachbaur, Herta Glassl, Michael Fiegl, Joseph Thaler, Guenther Gastl
Br J Haematol 120(1):63. [CrossRef]
The TCR Vβ repertoire usage of T-cells from cord blood induced by chronic myelogenous leukemia associated antigen
Yangqiu Li, Lijian Yang, Shaohua Chen, Yuping Zhang, Xiuli Wu
GHEM 10(5):387. [CrossRef]
Tania Crough, Mie Nieda, James Morton, John Bashford, Simon Durrant, Andrew Nicol
J Immunother 25(6):469. [CrossRef]
T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation
Johannes Schetelig, Alexander Kiani, Marc Schmitz, Gerhard Ehninger, Martin Bornhäuser
Cancer Immunol Immunother 54(11):1043. [CrossRef]
Akinobu Matsuzaki, Aiko Suminoe, Hiroyoshi Hattori, Takayuki Hoshina, Toshiro Hara
J Pediatr Hematol Oncol 24(3):220. [CrossRef]
Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia
H Gao, B-N Lee, M Talpaz, N J Donato, J E Cortes, H M Kantarjian, J M Reuben
19(11):1905. [CrossRef]
Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts
Kozo Masuda, Akio Hiraki, Nobuharu Fujii, Toshiyuki Watanabe, Motoyuki Tanaka, Kosei Matsue, Yoichiro Ogama, Mamoru Ouchida, Kenji Shimizu, Kazuma Ikeda
Cancer Sci 98(1):102. [CrossRef]
BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes
J H Kessler, S A Bres-vloemans, P A Van veelen, A De ru, I J G Huijbers, M Camps, A Mulder, R Offringa, J W Drijfhout, O C Leeksma
20(10):1738. [CrossRef]
Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation
M Bornhauser, C Thiede, J Babatz, J Schetelig, T Illmer, A Kiani, U Platzbecker, W Herr, E-P Rieber, G Ehninger
20(11):2055. [CrossRef]
Targeting pediatric malignancies for T cell-mediated immune responses
Crystal L. Mackall, Lee J. Helman
Curr Oncol Rep 2(6):539. [CrossRef]
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia
C. Quintarelli, G. Dotti, B. De angelis, V. Hoyos, M. Mims, L. Luciano, H. E. Heslop, C. M. Rooney, F. Pane, B. Savoldo
112(5):1876. [CrossRef]
Autologous and allogeneic high-dose therapy for melanoma
Kim A. Margolin
Curr Oncol Rep 3(4):338. [CrossRef]
Experimental and clinical approaches for optimization of the graft-versus-leukemia effect
Bart Van wijmeersch, Sabine Fevery, Mark Waer, An D Billiau, Ben Sprangers
Nat Clin Prac Oncol 4(7):404. [CrossRef]
T cell therapies following hematopoietic stem cell transplantation: surely there must be a better way than DLI?
A A Kennedy-nasser, C M Bollard
J Hum Hypertens 40(2):93. [CrossRef]
PR1 vaccination in myeloid malignancies
Katayoun Rezvani
Expert Rev Vaccines 7(7):867. [CrossRef]
Clinical developments in reduced intensity haematopoietic stem cell transplantation
William J Hogan, Rainer Storb
ebot 2(7):703. [CrossRef]
Translational Mini-Review Series on Vaccines:
Peptide vaccines for myeloid leukaemias
A. J. Barrett, K. Rezvani
Clin Exp Immunol 148(2):189. [CrossRef]
Identification of Human Tumor Antigens Recognized by T-Cells and Their Use for Immunotherapy
Yutaka Kawakami
Int J Hematol 77(5):427. [CrossRef]
Current status of peptide vaccines for cancer immunotherapy in malignant myeloid diseases
J. Greiner, M. Schmitt
memo 1(4):223. [CrossRef]
Association of HLA class II allele and haplotype frequencies with chronic myelogenous leukemia and age-at-onset of the disease
Ali-Akbar Amirzargar, Farideh Khosravi, S. Saied Dianat, Kamran Alimoghadam, Fereidoun Ghavamzadeh, Bita Ansaripour, Batool Moradi, Behrooz Nikbin
Pathol Oncol Res 13(1):47. [CrossRef]
CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT
M Kapp, S Stevanović, K Fick, S M Tan, J Loeffler, A Opitz, T Tonn, G Stuhler, H Einsele, G U Grigoleit
J Hum Hypertens 43(5):399. [CrossRef]
Targets for active immunotherapy against pediatric solid tumors
J. F. M. Jacobs, P. G. Coulie, C. G. Figdor, G. J. Adema, I. J. M. Vries, P. M. Hoogerbrugge
Cancer Immunol Immunother 58(6):831. [CrossRef]
BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors
Sylvie Rusakiewicz, Alejandro Madrigal, Paul Travers, Anthony I. Dodi
Cancer Immunol Immunother 58(9):1449. [CrossRef]
